Comparative Pharmacology
Head-to-head clinical analysis: JARDIANCE versus STEGLATRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JARDIANCE versus STEGLATRO.
JARDIANCE vs STEGLATRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose co-transporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, lowering blood glucose independent of insulin.
Steglatro (ertugliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose.
10 mg orally once daily, may increase to 25 mg orally once daily if tolerated and additional glycemic control needed.
0.5 mg orally once daily for patients with type 2 diabetes; no dose adjustment for age, gender, or race.
None Documented
None Documented
Terminal elimination half-life is approximately 12.9 hours in healthy subjects. Steady-state is achieved after 4-5 days of once-daily dosing. Effective half-life for accumulation: ~4-6 hours.
Terminal elimination half-life is approximately 12.4 hours in patients with type 2 diabetes, supporting once-daily dosing. No accumulation occurs at steady state.
Primarily renal: approximately 70-80% of absorbed dose excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal: ~10-20% via biliary and fecal elimination.
Approximately 65% of the dose is excreted in the urine as unchanged drug via active tubular secretion, and 35% is excreted in the feces as unchanged drug, indicating minimal metabolism.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor